Technology | Clinical Decision Support | February 14, 2018

FDA Clears First AI-Powered Clinical Decision Support Software for Stroke

Viz.AI Contact application uses artificial intelligence algorithm to analyze CT images for stroke indicators; approval paves way for future computer-aided triage software devices

FDA Clears First AI-Powered Clinical Decision Support Software for Stroke

February 14, 2018 — The U.S. Food and Drug Administration (FDA) announced marketing clearance for Viz.AI’s Contact application, the first artificial intelligence (AI)-based clinical decision support (CDS) solution cleared for sale in the U.S. Viz.AI Contact is designed to analyze computed tomography (CT) results that may notify providers of a potential stroke in their patients.

A stroke occurs if the flow of oxygen-rich blood to a portion of the brain is blocked, also known as an occlusion. According to the Centers for Disease Control and Prevention, stroke is the fifth leading cause of death in the U.S. and is a major cause of serious disability for adults. About 795,000 people in the U.S. have a stroke each year.

“Strokes can cause serious and irreversible damage to patients. The software device could benefit patients by notifying a specialist earlier thereby decreasing the time to treatment. Faster treatment may lessen the extent or progression of a stroke,” said Robert Ochs, Ph.D., acting deputy director for radiological health, Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health.

The Viz.AI Contact application is a computer-aided triage software that uses an artificial intelligence algorithm to analyze images for indicators associated with a stroke. These types of algorithms can assist providers in identifying the most appropriate treatment plan for a patient’s disease or condition. The FDA is currently creating a regulatory framework for these products that encourages developers to create, adapt and expand the functionalities of their software to aid providers in diagnosing and treating diseases and conditions.

The Viz.AI Contact application is designed to analyze CT images of the brain and send a text notification to a neurovascular specialist if a suspected large vessel occlusion (LVO) has been identified. The algorithm will automatically notify the specialist during the same time the first-line provider is conducting a standard review of the images, potentially involving the specialist sooner than the usual standard of care in which patients wait for a radiologist to review CT images and notify a neurovascular specialist. The notification can be sent to a mobile device, such as a smartphone or tablet, but the specialist still needs to review the images on a clinical workstation.

The Viz.AI Contact application is intended to be used by neurovascular specialists, such as vascular neurologists, neuro-interventional specialists or other professionals with similar training. The application is limited to analysis of imaging data and should not be used as a replacement of a full patient evaluation or solely relied upon to make or confirm a diagnosis.

The company submitted a retrospective study of 300 CT images that assessed the independent performance of the image analysis algorithm and notification functionality of the Viz.AI Contact application against the performance of two trained neuro-radiologists for the detection of large vessel blockages in the brain. Real-world evidence was used with a clinical study to demonstrate that the application could notify a neurovascular specialist sooner in cases where a blockage was suspected. The Viz.ai LVO Stroke Platform obtained an AUC of 0.91, identifying LVOs and alerting the relevant specialist with 90 percent sensitivity and specificity, and a median scan to notification time of under 6 minutes. In over 95 percent of cases, the automatic notifications demonstrated faster notification of the specialist, saving between 6 and 206 minutes, with an average time saving of 52 minutes.

The Viz.AI Contact application was reviewed through the De Novo premarket review pathway, a regulatory pathway for some new types of medical devices that are low to moderate risk and have no legally marketed predicate device to base a determination of substantial equivalence. This action also creates a new regulatory classification, which means that subsequent computer-aided triage software devices with the same medical imaging intended use may go through the FDA’s premarket 510(k) notification process, whereby devices can obtain marketing authorization by demonstrating substantial equivalence to a predicate device.

For more information: www.viz.ai

Related Artificial Intelligence Content

Advances in Cardiac Imaging Technologies at RSNA 2017

Technology Report: Artificial Intelligence at RSNA 2017

VIDEO: Examples of How Artificial Intelligence Will Improve Medical Imaging

VIDEO: Deep Learning is Key Technology Trend at RSNA 2017

VIDEO: How Utilization of Artificial Intelligence Will Impact Radiology

Why AI By Any Name Is Sweet For Radiology

 

Related Content

News | Artificial Intelligence

May 26, 2022 — At the 69th Annual Conference of the Israel Heart Society, UltraSight, an Israeli-based digital health ...

Home May 26, 2022
Home
News | Artificial Intelligence

May 24, 2022 — Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced that the U.S ...

Home May 24, 2022
Home
News | Artificial Intelligence
April 6, 2022 – Myocarditis (inflammation of the heart muscle) is usually caused by viruses, such as in Covid-19 disease ...
Home April 06, 2022
Home
News | Artificial Intelligence

April 2, 2022 — Aidoc, a leading provider of healthcare AI solutions, announced that it received FDA 510(k) clearance ...

Home April 02, 2022
Home
News | Artificial Intelligence
March 11, 2022 – The Department of Medicine at Cedars-Sinai has established a new division to explore how artificial ...
Home March 11, 2022
Home
News | Artificial Intelligence
Physician-scientists in the Smidt Heart Institute at Cedars-Sinai have created an artificial intelligence (AI) tool that ...
Home February 25, 2022
Home
Videos | Artificial Intelligence

Here are two examples of artificial intelligence (AI) driven pulmonary embolism (PE) response team apps featured by ...

Home January 13, 2022
Home
Feature | Artificial Intelligence | By Dave Fornell, DAIC Editor

Artificial intelligence (AI) has found a unique niche to help automate the activation of acute care teams for pulmonary ...

Home December 09, 2021
Home
News | Artificial Intelligence

December 2, 2021 — Artificial intelligence (AI) vendor DiA Imaging Analysis was featured in a recent study presented by ...

Home December 02, 2021
Home
News | Artificial Intelligence

November 22, 2021 — Cardiologs, a leader in artificial intelligence (AI) cardiology diagnostics, announced the results ...

Home November 22, 2021
Home
Subscribe Now